)
Visual
earnings real time
Royalty Pharma
Royalty Pharma (RPRX) investor relations material
Royalty Pharma 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Key business highlights and strategy
Achieved 14–16% growth in portfolio receipts for 2025, with strong returns on invested capital (15.7%) and equity (22.9%).
Internalized external management, reducing costs and improving governance.
Deployed $2.6B in value-creating royalty transactions, including eight new royalties and a landmark deal with Revolution Medicines.
Returned $1.2B to shareholders via share repurchases and increased dividends.
Consistently outperformed analyst expectations in 15 of the last 22 quarters.
Strategic vision and growth objectives
Aims to be the leading capital allocator in life sciences, targeting consistent, compounding growth.
Focuses on strong execution, rapid industry growth, and an optimized business model.
Maintains a dynamic capital allocation framework, balancing royalty investments and share repurchases based on market conditions.
Projects significant financial capacity, with $30 billion available for strategic initiatives through 2030.
Financial performance and capital deployment
Achieved 2025 portfolio receipts guidance midpoint of $3.225 billion, reflecting ~15% year-over-year growth.
Delivered double-digit average annual growth in royalty receipts since IPO, exceeding expectations in 15 of the last 22 quarters.
On track to meet or exceed the 5-year capital deployment target of $10–12 billion (2022–2026).
Return on Invested Capital averaged 14.8% annually, with Return on Invested Equity at 21.5%.
RP's dev-stage success rate is 90%. How
Synthetic royalties are 5% of biopharma funding. Why
How does RP balance royalty deals vs. buybacks
Ideal synthetic royalty deal characteristics?
China market unique challenges/advantages?
Factors for higher royalty capital deployment?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- ACE
Higher margins and PAT in Q3 FY26 despite flat revenue and lower sales volumes. - GODREJAGRO
Q3 FY26 revenue reached ₹2,718.32 crore with 33.9% adjusted PAT growth and strong segment gains. - QBY
Profitability returns in 2025, driven by sector focus, AI, and international expansion. - NAZARA
EBITDA and margins rose on IP focus, but regulatory changes led to major impairment losses. - HAPPYFORGE
Stable to growing financials, strong margins, and disciplined IPO fund use with no audit concerns. - RBA
Q3 revenue rose 16.5% in India; Inspira Global to acquire a controlling stake and infuse capital. - 6674
Profits and dividends revised upward on strong battery sales and improved margins. - BOROUGE
$1.1B net profit, 37% EBITDA margin, record sales, and major restructuring drive future growth. - 8059
Record Q3 profits and strong segment growth support an upwardly revised full-year outlook. - 7011
Strong order intake and profit growth drive upward revision of FY2025 forecasts and reflect key divestiture impact.
Next Royalty Pharma earnings date
Q4 202511 Feb, 2026
Royalty Pharma
Next Royalty Pharma earnings date
Q4 202511 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. The company's royalty acquisition segment engages in the acquisition of royalty streams from pharmaceutical companies. Its funding segment provides equity or loan financing to biotechnology companies developing innovative methods for the treatment of cancer, inflammatory disease, obesity, diabetes, and other metabolic disorders.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage